{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:03:14Z","timestamp":1780405394677,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer is a highly heterogeneous disease with varying responses to anti-cancer drugs. Although several attempts have been made to predict the anti-cancer therapeutic responses, there remains a great need to develop highly accurate prediction models of response to the anti-cancer drugs for clinical applications toward a personalized medicine. Patient derived xenografts (PDXs) are preclinical cancer models in which the tissue or cells from a patient\u2019s tumor are implanted into an immunodeficient or humanized mouse. In the present study, we develop a bioinformatics analysis pipeline to build a predictive gene expression model (GEM) for cancer patients\u2019 drug responses based on gene expression and drug activity data from PDX models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Drug sensitivity biomarkers were identified by performing an association analysis between gene expression levels and post-treatment tumor volume changes in PDX models. We built a drug response prediction model (called PDXGEM) in a random-forest algorithm by using a subset of the drug sensitvity biomarkers with concordant co-expression patterns between the PDXs and pretreatment cancer patient tumors. We applied the PDXGEM to several cytotoxic chemotherapies as well as targeted therapy agents that are used to treat breast cancer, pancreatic cancer, colorectal cancer, or non-small cell lung cancer. Significantly accurate predictions of PDXGEM for pathological response or survival outcomes were observed in extensive independent validations on multiple cancer patient datasets obtained from retrospective observational studies and prospective clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our results demonstrated the strong potential of using molecular profiles and drug activity data of PDX tumors in developing a clinically translatable predictive cancer biomarkers for cancer patients. The PDXGEM web application is publicly available at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/pdxgem.moffitt.org\">http:\/\/pdxgem.moffitt.org<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12859-020-03633-z","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T07:03:50Z","timestamp":1594019030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-0330","authenticated-orcid":false,"given":"Youngchul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daewon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"3633_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","volume":"108","author":"R Fisher","year":"2013","unstructured":"Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108:479\u201385.","journal-title":"Br J Cancer"},{"key":"3633_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamainternmed.2016.7761","volume":"177","author":"T Rupp","year":"2017","unstructured":"Rupp T, Zuckerman D. Quality of life, overall survival, and costs of Cancer drugs approved based on surrogate endpoints. JAMA Intern Med. 2017;177:276\u20137.","journal-title":"JAMA Intern Med"},{"key":"3633_CR3","doi-asserted-by":"publisher","first-page":"7655","DOI":"10.2174\/0929867325666180718164712","volume":"26","author":"J Zou","year":"2018","unstructured":"Zou J, Wang E. Cancer biomarker discovery for precision medicine: new progresses. Curr Med Chem. 2018;26:7655\u201371.","journal-title":"Curr Med Chem"},{"key":"3633_CR4","first-page":"256","volume":"4","author":"N Goossens","year":"2015","unstructured":"Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4:256\u201369.","journal-title":"Transl Cancer Res"},{"key":"3633_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-4615-8152-9_2","volume-title":"The NCI in vitro anticancer drug discovery screen. in anticancer drug development guide: preclinical screening, clinical trials, and approval","author":"MR Boyd","year":"1997","unstructured":"Boyd MR. In: Teicher BA, editor. The NCI in vitro anticancer drug discovery screen. in anticancer drug development guide: preclinical screening, clinical trials, and approval. Totowa: Humana Press; 1997. p. 23\u201342."},{"key":"3633_CR6","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, et al. Genomics of drug sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955\u201361.","journal-title":"Nucleic Acids Res"},{"key":"3633_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, et al. The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"3633_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nbt.3052","volume":"32","author":"M Bansal","year":"2014","unstructured":"Bansal M, et al. A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol. 2014;32:1213\u201322.","journal-title":"Nat Biotechnol"},{"key":"3633_CR9","doi-asserted-by":"publisher","first-page":"e30550","DOI":"10.1371\/journal.pone.0030550","volume":"7","author":"JS Ferriss","year":"2012","unstructured":"Ferriss JS, et al. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One. 2012;7:e30550.","journal-title":"PLoS One"},{"key":"3633_CR10","doi-asserted-by":"publisher","first-page":"e49529","DOI":"10.1371\/journal.pone.0049529","volume":"7","author":"K Shen","year":"2012","unstructured":"Shen K, et al. A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. PLoS One. 2012;7:e49529.","journal-title":"PLoS One"},{"key":"3633_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1078-0432.CCR-09-2247","volume":"16","author":"JK Lee","year":"2010","unstructured":"Lee JK, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2010;16:711\u20138.","journal-title":"Clin Cancer Res"},{"key":"3633_CR12","doi-asserted-by":"publisher","first-page":"e86532","DOI":"10.1371\/journal.pone.0086532","volume":"9","author":"Y Kim","year":"2014","unstructured":"Kim Y, et al. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS One. 2014;9:e86532.","journal-title":"PLoS One"},{"key":"3633_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.18632\/oncotarget.23124","volume":"9","author":"Y Kim","year":"2018","unstructured":"Kim Y, Dillon PM, Park T, Lee JK. CONCORD biomarker prediction for novel drug introduction to different cancer types. Oncotarget. 2018;9:1091\u2013106.","journal-title":"Oncotarget"},{"key":"3633_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc.2016.140","volume":"17","author":"AT Byrne","year":"2017","unstructured":"Byrne AT, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17:254\u201368.","journal-title":"Nat Rev Cancer"},{"key":"3633_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/1471-2164-15-393","volume":"15","author":"MG Hollingshead","year":"2014","unstructured":"Hollingshead MG, et al. Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies. BMC Genomics. 2014;15:393.","journal-title":"BMC Genomics"},{"key":"3633_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Dis. 2014;4:998\u20131013.","journal-title":"Cancer Dis"},{"key":"3633_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","volume":"167","author":"A Bruna","year":"2016","unstructured":"Bruna A, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell. 2016;167:260\u2013274 e222.","journal-title":"Cell"},{"key":"3633_CR18","doi-asserted-by":"publisher","first-page":"13550","DOI":"10.1073\/pnas.0506230102","volume":"102","author":"LD Miller","year":"2005","unstructured":"Miller LD, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102:13550\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3633_CR19","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-10-1265","volume":"16","author":"A Tabchy","year":"2010","unstructured":"Tabchy A, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010;16:5351\u201361.","journal-title":"Clin Cancer Res"},{"key":"3633_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10549-011-1895-2","volume":"132","author":"LJ Esserman","year":"2012","unstructured":"Esserman LJ, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132:1049\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"3633_CR21","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1158\/1078-0432.CCR-12-1359","volume":"19","author":"CE Horak","year":"2013","unstructured":"Horak CE, et al. Biomarker analysis of neoadjuvant doxorubicin\/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer. Clin Cancer Res. 2013;19:1587\u201395.","journal-title":"Clin Cancer Res"},{"key":"3633_CR22","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jama.2011.593","volume":"305","author":"C Hatzis","year":"2011","unstructured":"Hatzis C, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305:1873\u201381.","journal-title":"JAMA"},{"key":"3633_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1349-7006.2012.02231.x","volume":"103","author":"T Miyake","year":"2012","unstructured":"Miyake T, et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci. 2012;103:913\u201320.","journal-title":"Cancer Sci"},{"key":"3633_CR24","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/bcr2468","volume":"12","author":"V Popovici","year":"2010","unstructured":"Popovici V, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010;12:R5.","journal-title":"Breast Cancer Res"},{"key":"3633_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273\u201383.","journal-title":"N Engl J Med"},{"key":"3633_CR26","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1038\/sj.onc.1206779","volume":"22","author":"S Menard","year":"2003","unstructured":"Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22:6570\u20138.","journal-title":"Oncogene"},{"key":"3633_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1200\/JCO.2014.57.6298","volume":"33","author":"EA Perez","year":"2015","unstructured":"Perez EA, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central Cancer treatment group n9831 adjuvant Trastuzumab trial. J Clin Oncol. 2015;33:701\u20138.","journal-title":"J Clin Oncol"},{"key":"3633_CR28","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ijms18071338","volume":"18","author":"A Adamska","year":"2017","unstructured":"Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18:1338.","journal-title":"Int J Mol Sci"},{"key":"3633_CR29","first-page":"2016","volume":"55","author":"L Badea","year":"2008","unstructured":"Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55:2016\u201327.","journal-title":"Hepatogastroenterology"},{"key":"3633_CR30","doi-asserted-by":"publisher","first-page":"e0133562","DOI":"10.1371\/journal.pone.0133562","volume":"10","author":"DT Chen","year":"2015","unstructured":"Chen DT, et al. Prognostic fifteen-gene signature for early stage pancreatic ductal adenocarcinoma. PLoS One. 2015;10:e0133562.","journal-title":"PLoS One"},{"key":"3633_CR31","doi-asserted-by":"crossref","unstructured":"Christof Winter, Glen Kristiansen, Stephan Kersting, Janine Roy, Daniela Aust, Thomas Kn\u00f6sel, Petra R\u00fcmmele, Beatrix Jahnke, Vera Hentrich, Felix R\u00fcckert, Marco Niedergethmann, Wilko Weichert, Marcus Bahra, Hans J. Schlitt, Utz Settmacher, Helmut Friess, Markus B\u00fcchler, Hans-Detlev Saeger, Michael Schroeder, Christian Pilarsky, Robert Gr\u00fctzmann, Donna K. Slonim. Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based. Ranking of Marker Genes. PLoS Computational Biology 8(5):e1002511.","DOI":"10.1371\/journal.pcbi.1002511"},{"key":"3633_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500\u2013U140.","journal-title":"Nat Med"},{"key":"3633_CR33","first-page":"bar026","volume":"2011","author":"JJ Zhang","year":"2011","unstructured":"Zhang JJ, et al. International Cancer genome consortium data portal-a one-stop shop for cancer genomics data. Database. 2011;2011:bar026.","journal-title":"Database"},{"key":"3633_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12094-011-0676-z","volume":"13","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, et al. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol. 2011;13:419\u201325.","journal-title":"Clin Transl Oncol"},{"key":"3633_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/pgs.10.188","volume":"12","author":"FA Muhale","year":"2011","unstructured":"Muhale FA, Wetmore BA, Thomas RS, McLeod HL. Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics. 2011;12:341\u201350.","journal-title":"Pharmacogenomics"},{"key":"3633_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2006.07.4187","volume":"25","author":"M Del Rio","year":"2007","unstructured":"Del Rio M, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 2007;25:773\u201380.","journal-title":"J Clin Oncol"},{"key":"3633_CR37","doi-asserted-by":"publisher","first-page":"e1001453","DOI":"10.1371\/journal.pmed.1001453","volume":"10","author":"L Marisa","year":"2013","unstructured":"Marisa L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10:e1001453.","journal-title":"PLoS Med"},{"key":"3633_CR38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/annonc\/mdn680","volume":"20","author":"M Ychou","year":"2009","unstructured":"Ychou M, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02\/FFCD9802). Ann Oncol. 2009;20:674\u201380.","journal-title":"Ann Oncol"},{"key":"3633_CR39","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, et al. Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117\u201325.","journal-title":"J Clin Oncol"},{"key":"3633_CR40","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","volume":"25","author":"S Khambata-Ford","year":"2007","unstructured":"Khambata-Ford S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230\u20137.","journal-title":"J Clin Oncol"},{"key":"3633_CR41","doi-asserted-by":"publisher","first-page":"9732","DOI":"10.3748\/wjg.v20.i29.9732","volume":"20","author":"A De Stefano","year":"2014","unstructured":"De Stefano A, Carlomagno C. Beyond KRAS: predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol. 2014;20:9732\u201343.","journal-title":"World J Gastroenterol"},{"key":"3633_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288\u2013300.","journal-title":"Transl Lung Cancer Res"},{"key":"3633_CR43","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/bioinformatics\/btt492","volume":"29","author":"AL Tarca","year":"2013","unstructured":"Tarca AL, et al. Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER diagnostic signature challenge. Bioinformatics. 2013;29:2892\u20139.","journal-title":"Bioinformatics"},{"key":"3633_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/1471-2164-7-289","volume":"7","author":"JM Balko","year":"2006","unstructured":"Balko JM, et al. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics. 2006;7:289.","journal-title":"BMC Genomics"},{"key":"3633_CR45","doi-asserted-by":"publisher","first-page":"e72966","DOI":"10.1371\/journal.pone.0072966","volume":"8","author":"F Baty","year":"2013","unstructured":"Baty F, et al. EGFR exon-level biomarkers of the response to bevacizumab\/erlotinib in non-small cell lung cancer. PLoS One. 2013;8:e72966.","journal-title":"PLoS One"},{"key":"3633_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19:279\u201390.","journal-title":"Clin Cancer Res"},{"key":"3633_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-015-0384-3","volume":"14","author":"DK Chang","year":"2015","unstructured":"Chang DK, et al. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol Cancer. 2015;14:119.","journal-title":"Mol Cancer"},{"key":"3633_CR48","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1093\/bioinformatics\/bth449","volume":"20","author":"JM Wettenhall","year":"2004","unstructured":"Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004;20:3705\u20136.","journal-title":"Bioinformatics"},{"key":"3633_CR49","first-page":"e28966","volume":"17","author":"M Wainberg","year":"2016","unstructured":"Wainberg M, Alipanahi B, Frey BJ. Are random forests truly the best classifiers? J Mach Learn Res. 2016;17:e28966.","journal-title":"J Mach Learn Res"},{"key":"3633_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"LI Lin","year":"1989","unstructured":"Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255\u201368.","journal-title":"Biometrics"},{"key":"3633_CR51","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03633-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-020-03633-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-020-03633-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T15:06:11Z","timestamp":1650207971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-020-03633-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3633"],"URL":"https:\/\/doi.org\/10.1186\/s12859-020-03633-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/686667","asserted-by":"object"}]},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}